Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.
Advertisement

Related Content

Faced With Adverse Patent Rulings, Pfizer Voices Concern About India’s Deteriorating Business Environment
A Closer Look: Gilead’s Viread Donation To China
China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs
China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs
India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
Bayer Donates A Second-line Defense Against China's Swelling Multidrug-resistant Tuberculosis
Thailand's Cost Control Measures And What They Mean For Pharma - IMS Analysis
ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
Advertisement
UsernamePublicRestriction

Register

SC078698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel